Stockscreener 앱 받기
19.96
2.67%
0.52
시간 외 거래:
19.57
-0.39
-1.95%
전일 마감가:
$19.44
열려 있는:
$19.33
하루 거래량:
505.90K
Relative Volume:
1.01
시가총액:
$566.88M
수익:
$320.35M
순이익/손실:
$-75.01M
주가수익비율:
-8.333
EPS:
-2.3953
순현금흐름:
$-113.17M
1주 성능:
+10.89%
1개월 성능:
+12.96%
6개월 성능:
-25.30%
1년 성능:
+1.84%
1일 변동 폭
$19.33
$20.00
1주일 범위
$17.74
$20.00
52주 변동 폭
$13.46
$31.04
Fulgent Genetics Inc Stock (FLGT) Company Profile
명칭
Fulgent Genetics Inc
전화
626-350-0537
주소
4399 SANTA ANITA AVE, EL MONTE
Compare FLGT vs TMO, DHR, IDXX, A, NTRA
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FLGT
Fulgent Genetics Inc
|
19.96 | 552.11M | 320.35M | -75.01M | -113.17M | -2.3953 |
TMO
Thermo Fisher Scientific Inc
|
513.03 | 187.95B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.19 | 136.75B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
551.50 | 43.78B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
136.01 | 38.27B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.91 | 37.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
Fulgent Genetics Inc Stock (FLGT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-05 | 업그레이드 | UBS | Neutral → Buy |
| 2023-12-07 | 개시 | UBS | Neutral |
| 2022-12-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-11-18 | 개시 | Raymond James | Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-02-04 | 재개 | Piper Sandler | Overweight |
| 2021-08-05 | 재개 | Credit Suisse | Underperform |
| 2021-01-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2020-11-24 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-08-20 | 개시 | Oppenheimer | Outperform |
| 2020-05-29 | 개시 | BTIG Research | Buy |
| 2019-11-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-03-01 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-11-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
모두보기
Fulgent Genetics Inc 주식(FLGT)의 최신 뉴스
Fulgent Genetics, Inc. Actuals & Estimates (NASDAQ:FLGT) - TradingView
Fulgent Genetics Inc (FLGT) Valuation: PE, PB & Fair Value Analysis - TradingKey
How (FLGT) Movements Inform Risk Allocation Models - Stock Traders Daily
Fulgent Genetics, Inc. Actuals & Estimates (BMV:FLGT) - TradingView
FLGT Forecast — Price Target — Prediction for 2027 - TradingView
Fulgent Genetics, Inc. Actuals & Estimates (BIVA:FLGT) - TradingView
Fulgent Genetics Inc (FLGT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Fulgent Genetics (FLGT) Stock Faces Mixed Analyst Target Changes After Margin Questions - Yahoo Finance Singapore
Fulgent Genetics Inc (FLGT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fulgent Genetics Inc (FLGT) Institutional Confidence - TradingKey
Fulgent Genetics Inc (FLGT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Fulgent Genetics Inc (FLGT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fulgent Genetics Inc. (FLGT) Q1 2026 Earnings: EPS Miss Widens, Yet Shares Buck the TrendEarnings Cycle Report - Město Břeclav
Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022. - marketscreener.com
Fulgent Genetics Inc (FLGT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fulgent Genetics Inc (FLGT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fulgent Genetics Inc (FLGT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fulgent Genetics unveils FulGenome upgrade with higher repeat expansion detection - Traders Union
Trading Systems Reacting to (FLGT) Volatility - Stock Traders Daily
Fulgent Deadline Alert - TMX Newsfile
How The Fulgent Genetics (FLGT) Investment Story Is Evolving With Recent Developments - Yahoo Finance
Fulgent Genetics Inc. (FLGT) Q1 2026 Earnings: Wide EPS Miss Sends Shares LowerLong-Term Guidance - newsline.com
Fulgent Genetics CSO Gao Hanlin sells $30,190 in stock By Investing.com - Investing.com Australia
How Fulgent Genetics Inc. (FLGT) Affects Rotational Strategy Timing - Stock Traders Daily
Fulgent Genetics CSO Gao Hanlin sells $30,190 in stock - Investing.com
Fulgent Genetics (NASDAQ: FLGT) insider sale covers RSU taxes - Stock Titan
Fulgent Genetics (FLGT) CFO reports tax withholding of vested RSU shares - Stock Titan
Fulgent Genetics (FLGT) CSO sells 1,688 shares to cover RSU tax - Stock Titan
Fulgent (NASDAQ: FLGT) CEO RSU vest triggers 4,392-share tax withholding - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) Form 144 lists 45,304 vested shares; small prior sale - Stock Titan
Fulgent Presents Updated Phase 2 FID-007 + Cetuximab Data at ASCO Showing 61.9% ORR - TradingView
Fulgent Genetics (FLGT) Presents Promising Data on Head and Neck Cancer Treatment - GuruFocus
Strong FID-007 Phase 2 results for Fulgent Genetics (NASDAQ: FLGT) - Stock Titan
Fulgent Presents Updated FID-007 Data at ASCO 2026 - The Joplin Globe
Fulgent Genetics COO Jian Xie sells $21,137 in company stock By Investing.com - Investing.com Australia
Fulgent Genetics COO Jian Xie sells $21,137 in company stock - Investing.com
Fulgent Genetics (NASDAQ: FLGT) exec sells shares for tax withholding - Stock Titan
[Form 4] Fulgent Genetics, Inc. Insider Trading Activity - Stock Titan
Fulgent Genetics (FLGT) CSO sells 945 shares to cover tax obligations - Stock Titan
Ming Hsieh (FLGT) reports 32% Fulgent Genetics stake and major share pledges - Stock Titan
Fulgent Genetics (FLGT) CEO reports RSU tax withholding and large trust holdings - Stock Titan
Fulgent Genetics (FLGT) price target decreased by 28.85% to 18.87 - MSN
FLGT Stock Price and Chart — NASDAQ:FLGT - TradingView
(FLGT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Law firm investigates Fulgent Genetics for possible securities law violations after revenue miss. - Pluang
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics - GlobeNewswire
Fulgent Genetics Presents Promising Phase 2 FID-007 & Cetuximab Data for Head and Neck Cancer at ASCO 2026 - Minichart
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting - BioSpace
Fulgent Announces Rapid Oral Full Abstract Publication for FID-00 - The National Law Review
Fulgent reports interim data for cancer drug FID-007 trial By Investing.com - Investing.com South Africa
Fulgent reports interim data for cancer drug FID-007 trial - Investing.com
Fulgent Genetics Inc (FLGT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.76%
0.62%
자본화:
|
볼륨(24시간):